Systemic Arterial Hypertension and Ophthalmohypertension as Independent Risk Factors for Poor Response to Antiangiogenic Therapy with Line 1 Drugs in Neovascular Age-related Macular Degeneration

Purpose: to assess hypertension as a risk factor for a poor response to antiangiogenic therapy.Patients and methods. Systemic blood pressure was studied in 84 patients (92 eyes) with age-related macular degeneration who were treated with intravitreal injections of Eilea in a fixed mode.Results. It w...

Full description

Saved in:
Bibliographic Details
Main Authors: V. G. Likhvantseva, A. S. Gevorgyan, S. G. Kapkova, S. I. Rychkova, T. E. Borisenko
Format: Article
Language:Russian
Published: Ophthalmology Publishing Group 2024-04-01
Series:Oftalʹmologiâ
Subjects:
Online Access:https://www.ophthalmojournal.com/opht/article/view/2301
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849687570245484544
author V. G. Likhvantseva
A. S. Gevorgyan
S. G. Kapkova
S. I. Rychkova
T. E. Borisenko
author_facet V. G. Likhvantseva
A. S. Gevorgyan
S. G. Kapkova
S. I. Rychkova
T. E. Borisenko
author_sort V. G. Likhvantseva
collection DOAJ
description Purpose: to assess hypertension as a risk factor for a poor response to antiangiogenic therapy.Patients and methods. Systemic blood pressure was studied in 84 patients (92 eyes) with age-related macular degeneration who were treated with intravitreal injections of Eilea in a fixed mode.Results. It was found that significantly more often a poor response to treatment in the form of partial non-resposing or progression of the disease, despite treatment, is associated with elevated diastolic blood pressure (DBP, p = 0.01). An increase in systolic (SBP) blood pressure in patients with arterial hypertension and AMD is accompanied by an increase in eye perfusion pressure (p < 0.01), which apparently worsens the absorption of angiostatics and causes a poor response to treatment. According to the results of the study, the most favorable corridor of SBP values associated with ideal response is in the range of values of 104–140 mm Hg, and DBP is in the range of 68–80 mm Hg st., which should be taken as the recommended parameters of blood pressure in patients with nVMD receiving a course of treatment for Eylea. Intraocular pressure (IOP) has demonstrated itself as a second modifiable independent and independent risk factor for poor response to treatment with nVMD with line 1 anti-VEGF therapy drugs. Intraocular pressure (IOP) has demonstrated itself as a second modifiable independent and independent risk factor for poor response to nVMD treatment with line 1 anti-VEGF therapy drugs. The biomarker associated with the ideal response was — 12.6 mm Hg, and the corridor of recommended values — 11–21 mm Hg. An increase in ophthalmotonus with the output of personalized values beyond this corridor seems to worsen the outcome of treatment.Conclusion. The identification of modifiable risk factors is extremely important in practical ophthalmology, as it opens up the possibility of increasing the patient’s chances of a better treatment outcome. Modifiable risk factors are valuable and powerful tools that replenish our arsenal. Information about them is important not only in the treatment of AMD, but can also be the patient’s motivation for switching to a healthy lifestyle and reducing the risk of developing the disease.
format Article
id doaj-art-04cfa673b2c24b7b8483c0cb63833e21
institution DOAJ
issn 1816-5095
2500-0845
language Russian
publishDate 2024-04-01
publisher Ophthalmology Publishing Group
record_format Article
series Oftalʹmologiâ
spelling doaj-art-04cfa673b2c24b7b8483c0cb63833e212025-08-20T03:22:18ZrusOphthalmology Publishing GroupOftalʹmologiâ1816-50952500-08452024-04-0121111712710.18008/1816-5095-2024-1-117-1271120Systemic Arterial Hypertension and Ophthalmohypertension as Independent Risk Factors for Poor Response to Antiangiogenic Therapy with Line 1 Drugs in Neovascular Age-related Macular DegenerationV. G. Likhvantseva0A. S. Gevorgyan1S. G. Kapkova2S. I. Rychkova3T. E. Borisenko4A.I. Burnasyan Federal Medical Biophysical Center of the Federal Medical Biological Agency; Academy of Postgraduate Education of the Federal Scientific and Clinical Center for Specialized Medical Assistance and Medical Technologies of Federal Medical Biological AgencyAcademy of Postgraduate Education of the Federal Scientific and Clinical Center for Specialized Medical Assistance and Medical Technologies of Federal Medical Biological AgencyA.I. Burnasyan Federal Medical Biophysical Center of the Federal Medical Biological Agency; Academy of Postgraduate Education of the Federal Scientific and Clinical Center for Specialized Medical Assistance and Medical Technologies of Federal Medical Biological AgencyA.A. Kharkevich Institute for Information Transmission Problems of the Russian Academy of Sciences; Medico-Biological University of Innovation and Continuing Education of Russian State Research Center — Burnasyan Federal Medical Biophysical Center of Federal Medical Biological AgencyResearch Institute of Eye Deseases named after M.M. KrasnovPurpose: to assess hypertension as a risk factor for a poor response to antiangiogenic therapy.Patients and methods. Systemic blood pressure was studied in 84 patients (92 eyes) with age-related macular degeneration who were treated with intravitreal injections of Eilea in a fixed mode.Results. It was found that significantly more often a poor response to treatment in the form of partial non-resposing or progression of the disease, despite treatment, is associated with elevated diastolic blood pressure (DBP, p = 0.01). An increase in systolic (SBP) blood pressure in patients with arterial hypertension and AMD is accompanied by an increase in eye perfusion pressure (p < 0.01), which apparently worsens the absorption of angiostatics and causes a poor response to treatment. According to the results of the study, the most favorable corridor of SBP values associated with ideal response is in the range of values of 104–140 mm Hg, and DBP is in the range of 68–80 mm Hg st., which should be taken as the recommended parameters of blood pressure in patients with nVMD receiving a course of treatment for Eylea. Intraocular pressure (IOP) has demonstrated itself as a second modifiable independent and independent risk factor for poor response to treatment with nVMD with line 1 anti-VEGF therapy drugs. Intraocular pressure (IOP) has demonstrated itself as a second modifiable independent and independent risk factor for poor response to nVMD treatment with line 1 anti-VEGF therapy drugs. The biomarker associated with the ideal response was — 12.6 mm Hg, and the corridor of recommended values — 11–21 mm Hg. An increase in ophthalmotonus with the output of personalized values beyond this corridor seems to worsen the outcome of treatment.Conclusion. The identification of modifiable risk factors is extremely important in practical ophthalmology, as it opens up the possibility of increasing the patient’s chances of a better treatment outcome. Modifiable risk factors are valuable and powerful tools that replenish our arsenal. Information about them is important not only in the treatment of AMD, but can also be the patient’s motivation for switching to a healthy lifestyle and reducing the risk of developing the disease.https://www.ophthalmojournal.com/opht/article/view/2301age-related macular degenerationantiangiogenic therapyrisk factor for poor response to treatmentarterial hypertensionophthalmohypertension
spellingShingle V. G. Likhvantseva
A. S. Gevorgyan
S. G. Kapkova
S. I. Rychkova
T. E. Borisenko
Systemic Arterial Hypertension and Ophthalmohypertension as Independent Risk Factors for Poor Response to Antiangiogenic Therapy with Line 1 Drugs in Neovascular Age-related Macular Degeneration
Oftalʹmologiâ
age-related macular degeneration
antiangiogenic therapy
risk factor for poor response to treatment
arterial hypertension
ophthalmohypertension
title Systemic Arterial Hypertension and Ophthalmohypertension as Independent Risk Factors for Poor Response to Antiangiogenic Therapy with Line 1 Drugs in Neovascular Age-related Macular Degeneration
title_full Systemic Arterial Hypertension and Ophthalmohypertension as Independent Risk Factors for Poor Response to Antiangiogenic Therapy with Line 1 Drugs in Neovascular Age-related Macular Degeneration
title_fullStr Systemic Arterial Hypertension and Ophthalmohypertension as Independent Risk Factors for Poor Response to Antiangiogenic Therapy with Line 1 Drugs in Neovascular Age-related Macular Degeneration
title_full_unstemmed Systemic Arterial Hypertension and Ophthalmohypertension as Independent Risk Factors for Poor Response to Antiangiogenic Therapy with Line 1 Drugs in Neovascular Age-related Macular Degeneration
title_short Systemic Arterial Hypertension and Ophthalmohypertension as Independent Risk Factors for Poor Response to Antiangiogenic Therapy with Line 1 Drugs in Neovascular Age-related Macular Degeneration
title_sort systemic arterial hypertension and ophthalmohypertension as independent risk factors for poor response to antiangiogenic therapy with line 1 drugs in neovascular age related macular degeneration
topic age-related macular degeneration
antiangiogenic therapy
risk factor for poor response to treatment
arterial hypertension
ophthalmohypertension
url https://www.ophthalmojournal.com/opht/article/view/2301
work_keys_str_mv AT vglikhvantseva systemicarterialhypertensionandophthalmohypertensionasindependentriskfactorsforpoorresponsetoantiangiogenictherapywithline1drugsinneovascularagerelatedmaculardegeneration
AT asgevorgyan systemicarterialhypertensionandophthalmohypertensionasindependentriskfactorsforpoorresponsetoantiangiogenictherapywithline1drugsinneovascularagerelatedmaculardegeneration
AT sgkapkova systemicarterialhypertensionandophthalmohypertensionasindependentriskfactorsforpoorresponsetoantiangiogenictherapywithline1drugsinneovascularagerelatedmaculardegeneration
AT sirychkova systemicarterialhypertensionandophthalmohypertensionasindependentriskfactorsforpoorresponsetoantiangiogenictherapywithline1drugsinneovascularagerelatedmaculardegeneration
AT teborisenko systemicarterialhypertensionandophthalmohypertensionasindependentriskfactorsforpoorresponsetoantiangiogenictherapywithline1drugsinneovascularagerelatedmaculardegeneration